← 홈

Catalyst · Landscape

향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS

Phase landscape

큐레이션·FDA·임상 3건 이상 프로그램 2033개

Preclinical
113
Phase 1
393
Phase 2
1020
Phase 3
383
Approved
124

Catalyst target · modality

향후 6개월 catalyst 2건 · 타깃·모달리티 분포

ADC 2
HER2
2

향후 6개월 Catalyst(2 / 60)

완료 예정프로그램PhaseStatusEndpoint신뢰도NCT
2026년 7월Enhertu (trastuzumab deruxtecan)ADC · HER2Phase 2Not yet recruitingIntracranial objective response rate(IC-ORR)보통NCT06088056
2026년 7월Enhertu (trastuzumab deruxtecan)ADC · HER2Phase 1Active, not recruitingIncidence of dose limiting toxicities in Phase 1a monotherapy; Incidence of adverse events in Phase 1a monotherapy; incidence of laboratory abnormalities in Phase 1a monotherapy; incidence of ECG abnormalities in Phase 1a monotherapy; incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd); Incidence of adverse events in Phase 1a combination with T-DXd; incidence of laboratory abnormalities in Phase 1a combination with T-DXd; incidence of ECG abnormalities in Phase 1a combination with T-DXd; incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1); Incidence of adverse events in Phase 1a combination with T-DM1; incidence of laboratory abnormalities in Phase 1a combination with T-DM1; incidence of ECG abnormalities in Phase 1a combination with T-DM1; Incidence of adverse events in Phase 1b monotherapy; incidence of laboratory abnormalities in Phase 1b monotherapy; incidence of ECG abnormalities in Phase 1b monotherapy신뢰 높음NCT05650879